Morera J, Vidal R, Morell F, Ruiz J, Bernadó L, Laporte J R
Eur J Clin Pharmacol. 1983;24(5):591-3. doi: 10.1007/BF00542206.
Of 25 cases of idiopathic pulmonary fibrosis, confirmed by open chest lung biopsy between January 1979 and July 1981, 5 patients had been taking amiodarone in doses less than 600 mg daily for 1 to 6 years. No lung disease had been observed in any patient before the administration of amiodarone, and other drugs, factors and diseases thought to play a role in the causation of pulmonary fibrosis were ruled out. Two patients died of respiratory insufficiency, and only 1 does not now suffer from serious sequelae. Review of a further 5 cases reported in the literature and the present data suggest a causal link between administration of amiodarone and pulmonary fibrosis, and tend to indicate a hypersensitivity mechanism.
在1979年1月至1981年7月间经开胸肺活检确诊的25例特发性肺纤维化病例中,有5例患者曾每日服用剂量小于600毫克的胺碘酮,持续1至6年。在服用胺碘酮之前,任何患者均未观察到肺部疾病,并且排除了其他被认为在肺纤维化病因中起作用的药物、因素和疾病。2例患者死于呼吸功能不全,目前只有1例未患有严重后遗症。对文献中报道的另外5例病例以及现有数据的回顾表明,胺碘酮的使用与肺纤维化之间存在因果关系,并倾向于表明存在超敏反应机制。